Immunogenic compositions comprising OMVs, an acellular pertussis antigen, a tetanus toxoid and a diphtheria toxoid
AssigneeGlaxosmithkline Biologicals SA
InventorsMario Contorni, Mariagrazia Pizza, Anja Seubert
Life of this patent
Estimating the term…
Abstract
The invention provides an immunogenic composition comprising OMVs and (a) acellular pertussis antigen, (b) a tetanus toxoid and (c) a diphtheria toxoid, wherein the OMVs are derived from Bordetella pertussis. The invention also provides compositions for use in a method for raising an immune response in a patient, comprising the step of administering to the patient a composition of the invention.
Claims19
An immunogenic composition comprising (a) Outer Membrane Vesicles (OMVs), (b) an acellular pertussis antigen, (c) a tetanus toxoid and (d) a diphtheria toxoid, wherein the OMVs are derived from a Bordetella pertussis strain comprising an S1 gene which has been modified to include the mutations R9K and E129G and which expresses a genetically detoxified pertussis toxoid PT 9K/129G;
- wherein the OMVs are not treated or chemically detoxified by treatment with formaldehyde, formalin, glutaraldehyde, hydrogen peroxide or a combination thereof.
Dependencies are inferred from the claim text.